British Journal of Dermatology
British Journal of Dermatology
4 years ago

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial

A. Radin, T.A. Luger, A. Tsianakas
Background Dupilumab, a human anti-interleukin-4 receptor α monoclonal antibody, significantly improved clinical signs and symptoms in adults with moderate-to-severe atopic dermatitis (AD) in a randomized, double-blind, placebo-controlled, phase 2a trial. Objectives We evaluate health-related quality of life (HRQoL) and correlation of HRQoL with secondary clinical and patient-reported outcomes in a subset of patients from this trial of dupilumab. Methods Patients were randomized to 300 mg weekly subcutaneous dupilumab or placebo for 12 weeks (NCT01548404). The QoL Index for AD (QoLIAD) score (exploratory outcome) and its correlation with efficacy outcomes (Eczema Area and Severity Index [EASI; primary endpoint], SCORing Atopic Dermatitis [SCORAD], SCORAD visual analogue scale [VAS] scores for sleep and pruritus, pruritus numerical rating scale [NRS] and 5-dimensional pruritus) were assessed in 64 adults with moderate-to-severe AD. Results Mean QoLIAD scores at baseline (± standard error [SE]) were 13.3 (±1.34) and 11.3 (±1.09) for the placebo and dupilumab group, respectively. Dupilumab significantly improved QoLIAD score after 12 weeks of treatment vs. placebo (mean percent change from baseline in QoLIAD score [±SE]: −64.0 [±6.91] vs. –11.1 [±9.31]). Least squares mean % difference from baseline vs. placebo in QoLIAD score (±SE) was −52.0 (±11.43; P<0.0001). QoLIAD scores significantly correlated with changes in efficacy outcomes, including EASI (r=0.4355), 5-dimensional pruritus (r=0.4937), pruritus NRS (r=0.4064), total SCORAD (r=0.5559), and SCORAD VAS scores for sleep (r=0.4681) and pruritus (r=0.5400); all P<0.05. Conclusions Dupilumab improved QoLIAD scores in adults with AD and was significantly associated with improvements in study outcomes This article is protected by copyright. All rights reserved.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/bjd.15905

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.